To Help Accelerate Development of Cancer Treatments with Real-World Data, COTA Welcomes Kevin Schweikert as Vice President, Life Sciences
COTA is pleased to announce Kevin Schweikert has joined the company as vice president, life sciences. With more than 20 years of experience in life sciences business development, Kevin has partnered with the most innovative pharmaceutical companies in the business, and the vendors these companies turn to for real-world data and analytics.
From Regulatory to RWD: A Journey to Improve Cancer Care with COTA
Working with the FDA and now COTA Laura describes why real-world data is an integral part of today’s patient care.
COTA Promotes Paige Whitney to Senior Vice President to Expand the Use of Real-World Data in Life Sciences
Paige Whitney will join the executive leadership team as Senior Vice President of Life Sciences. Paige is responsible for growing the company’s industry partnerships and strengthening COTA’s position as a leading provider of oncology RWD.
The Roadmap for Making Clinical Trials More Diverse and Representative
Diversity in clinical trials is a change that needs to be made in order to make all efforts more efficient and develop a better ending result for patients. Karla Feghali and Laura Fernandes detail why this is so necessary moving forwards.
Real-World Data Champion Robert Califf Nominated for FDA Commissioner
Dr. Califf is a staunch advocate for the use of real-world data (RWD) and real-world evidence (RWE) in the clinical trial ecosystem, with a long history of leveraging RWD and RWE to transform the life sciences community.
Roche is Validating the Utility of Real-World Evidence as a comparator to Single-arm Clinical Trials
A new study from Roche finds concerns around real-world evidence as a comparator to single-arm trials may be unfounded.
Health Evolution Features COTA’s Advancements With RWE & COVID-19
Along with COTA’s data analytics expertise, Hackensack Meridian Health has been pioneering some of the early work to understand COVID-19. Stuart Goldberg, MD, chief of the Division of Outcomes and Value Research at the John Theurer Cancer Center and Mike Doyle, CEO of COTA, recently spoke with Health Evolution about the findings so far, and how we continue to learn from existing patients.
COTA’s Mike Doyle Reflects on COVID-19 as a CEO & Health Data Veteran
In two recent articles, COTA CEO Mike Doyle reflects on how the pandemic is challenging leaders to be flexible and, specifically in healthcare, how data companies can be doing more.
COTA Participates in Reagan-Udall Foundation + Friends of Cancer Research COVID-19 Evidence Accelerator
COTA is actively participating in this collaboration, presenting key findings from ongoing research with Hackensack-Meridian Health involving observational, real-world studies of more than 3,000 hospitalized COVID-19 patients.
